POST Online Media Lite Edition



 

Scancell plans new COVID vaccine trial in South Africa, UK

Christian Fernsby |
Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces an update on COVIDITY clinical trial plans and the publication of preclinical data on two vaccine candidates from its COVIDITY research programme.

Article continues below




The COVIDITY programme is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University and the programme has received funding from Innovate UK.

Following findings from the preclinical data, a Phase 1 study on this next generation vaccine will commence in both South Africa and the UK in the second half of this year subject to local regulatory approvals.

Preclinical data published on vaccine candidates SCOV1 (SN15) and SCOV2 (SN17) The Company is pleased to note the publication of preclinical data on its two lead bivalent vaccine candidates SN15 (also known as SCOV1) and SN17 (also known as SCOV2).

These next generation COVID-19 vaccines could offer improved protection against new SARS-Cov-2 variants of concern (VoC) due to the inclusion of the highly conserved nucleocapsid N antigen in addition to the more variable spike (S) protein.

Based on the potent immune responses generated in these preclinical studies, Scancell plans to test the safety and immunogenicity of SCOV1 and SCOV2 in a Phase 1 clinical trial.

SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology and have a dual mechanism of action to induce high avidity T-cell immune responses against both the N and S viral antigens.

Targeting the receptor-binding domain (RBD) of the S antigen, the vaccines also elicit high titre virus-neutralising antibodies (VNAbs) that can cross-react against a range of VoCs, including the Beta variant first identified in South Africa.

The paper shows that SN15 elicits strong pro-inflammatory T-cell responses to both the N and S proteins, with these responses being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc utilising Scancell’s AvidiMab™ technology.

The SN15 vaccine also stimulates high titre neutralising antibody (VNAbs) responses to the receptor binding domain (RBD) of the S protein and shows cross reactivity with S proteins from the emerging variants Alpha (B.1.1.7; Kent) and Beta (B.1.351; South African).

The Company believes this DNA platform can be easily adapted to target variant RBD and N proteins and demonstrates that SN17, encoding the Beta RBD sequence, stimulates cross-reactive antibody mediated and T-cell immunity.

The paper supports the translation of this DNA vaccine platform into the clinic, thereby offering a particular advantage for targeting emerging SARS-CoV-2 variants.

Prof Lindy Durrant, Founder and Chief Scientific Officer, Scancell, commented: “We believe that the combination of cross-reactive VNAbs with durable memory responses against the conserved N protein may confer an added advantage by eliciting potent T cells that can destroy cells infected with any of the variant viruses, providing an extra layer of protective surveillance.” The preclinical data and paper titled “A novel bivalent DNA vaccine encoding both spike protein receptorbinding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants” can be viewed via BioRxiv.

Part 1 of clinical trial (South Africa) A regulatory application to initiate a Phase 1 clinical trial of COVIDITY has been submitted to the South African Health Products Regulatory Authority (SAHPRA).

Part 1 of this study will be conducted at the University of Cape Town Lung Institute, South Africa, in COVID-19-naïve unvaccinated, healthy adult volunteers.

Such a study is not possible in the UK because of the rapid rollout of the vaccination programme.

The objective of the study will be to assess the safety and immunogenicity of the two candidates in unvaccinated individuals and will have two cohorts assessing different doses of SCOV1 and SCOV2 using two different needle-free injection methods.

In addition to evaluating the VNAbs, the Company will also analyse the T cell responses to the N protein, which will provide additional information and data on the potential utility of both SCOV1 and SCOV2 against future SARS-CoV-2 variants.

Part 2 of clinical trial (UK) After demonstration of safety in Part 1 of the COVIDITY study in South Africa, Scancell will seek approval from the Medicines & Healthcare products Regulatory Agency (MHRA) to initiate a UK extension of the study in which SCOV2 will be given to healthy volunteers who have already received two doses of an approved vaccine.

The immune responses from this UK part of the COVIDITY study will allow the Company to assess the ability of SCOV2 to boost the immune response against current and potential future strains of COVID-19 in prevaccinated individuals.

Vaccine manufacturing As reported in October 2020, the Company entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of plasmids for Scancell’s COVID-19 vaccine.

The collaboration is progressing to plan to ensure that Good Manufacturing Practice (GMP) grade SCOV1 clinical trial supplies are available for initiation of the COVIDITY study followed by SCOV2 supplies for further clinical assessments.

Dr Cliff Holloway, Chief Executive Officer, Scancell, commented: "There is a significant threat from future mutations of the SARS-CoV-2 virus, as we have seen with the rapid transmission of the Delta variant.

"Our next generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2.

"We look forward to initiating this trial in South Africa and the UK, and to updating the market in due course on further developments from the COVIDITY programme.”


What to read next

World-first COVID-19 alternating dose vaccine study launches in UK
WHO validates Sinovac COVID-19 vaccine for emergency use
Moderna begins testing next-generation coronavirus vaccine

U.S. preliminarily finds some companies circumventing solar tariffs

 
The US Department of Commerce on Friday published its preliminary determination in a solar circumvention case, finding that certain companies in four Southeast Asian countries are dodging US duties on Chinese solar cells and modules.
 
 

Latest

Norwegian seafood exports in November increased
Germany: InvestEU - EIB invests in PBT’s eco-friendly battery material production
James Webb telescope produces an unparalleled view of the ghostly light in galaxy clusters
Currys: Amazon uses UK infrastructure while not paying enough tax

NEWS

Arctic blast set to freeze Britain as temperatures plunge to -8C

Poland: CBA detained two more persons in financial pyramid case
Flight from Poland diverted to Prague after possible bomb threat
Spain dismantles criminal organization dedicated to "CEO fraud" that operated nationally and internationally
UK rail dispute continues, union rejects latest offer from employers
South Africa: AFU seizes $2 million in assets held by corruption accused
 

BUSINESS

Switzerland watchdog investigates labour market in banking sector

EU’s embargo on Russian oil shipments, price cap mechanism come into force
Worldwide PC shipments declined 19.5% in third quarter of 2022
Highlights: November 28, 2022 - December 2, 2022
Air pollution hurts Bangladesh GDP and health
Iran begins procedures to build Darkhovin Nuclear Plant
 

Trending Now

Norwegian seafood exports in November increased

Worldwide PC shipments declined 19.5% in third quarter of 2022

U.S. preliminarily finds some companies circumventing solar tariffs

Commission opens in-depth investigation into Lithuanian measure to compensate Litgas for operation of LNG terminal


POLITICS

Commission opens in-depth investigation into Lithuanian measure to compensate Litgas for operation of LNG terminal

Indonesia plans to build nuclear power plant
€13.5 billion French scheme to compensate energy-intensive companies for indirect emission costs
UK: Business Secretary launches review to prevent small firms from being ripped off by larger companies
UK government could bring in military to ease strike action, Sunak may prepare new ban on strike
Moscow will not accept price cap on Russian oil
 

Today We Recommend

Trafigura enters $3 bln loan to supply Germany's Sefe with gas


Highlights 

Iran’s shrimp exports to Russia up by 350% this year

Global food prices overall hold steady in November

Essar plans $4.9 bln petrochemical complex in Odisha


COMPANIES

New Zealand mulls law to make Google, Meta pay for news content

John Lewis Partnership to build 1,000 rental homes
Trafigura enters $3 bln loan to supply Germany's Sefe with gas
New Zealand fines sunscreen company for claims that could not be backed up
ALDI can acquire Altmühltaler Mineralbrunnen, Schwarz Group can take over Erfurter Teigwaren
Austria: EIB supports RLB NÖ-Wien's investments in renewable energy and energy efficiency
 

CAREERS

Boeing appoints Brendan Nelson as Boeing International

Totally appoints John McMullan as medical director
Derby Building Products promotes Michael Morris to SVP
Former UK CMA CEO Andrea Coscelli to join Keystone
US Foods appoints Dave Flitman as CEO
G Mining Ventures appoints Carlos Vilhena to board
 

ECONOMY

CBI severely downgrades UK growth forecast

Japan services PMI continued to expand in November
Italy: GDP growth loses momentum in Q3
Indonesia: Inflation declines to lowest level since August in November
Australia retail sales contract in October
Cyprus' GDP growth estimated at 5.4 pct in Q3
 

EARNINGS

Genesco Q3 2023 GAAP earnings $1.66

Kirkland's Q3 sales $131.0 million
Cracker Barrel Old Country Store Q1 2023 revenue $839.5 million
Malvern Bancorp Q4 net income $2.6 million
Big Lots Q3 loss $4.33 million
Kroger Q3 profit decreases
 

OP-ED

Micromanaging is the worst enemy of efficiency and teamwork

Niger set to monetize massive gas reserves through Saharan natural gas pipeline
Putting the brakes on EV folly that choked the market
Oil discovery in Kavango Basin may mean huge benefits for Namibians
Cape Town and Dubai battle over Africa's energy future
Is America going to lose its superpower status?
 

AGRIFISH

Iran’s shrimp exports to Russia up by 350% this year

High pathogenic avian influenza confirmed in Columbia County, Oregon
Sanitary certificate to export bovine meat from Argentina agreed with Mexico
Czech Republic detects first African swine fever case in 5 years
Dutch cattle herd size barely changed in 2022
Global food prices overall hold steady in November
 

LEADERSHIP

Only 32% of employees believe their pay is fair

Corporate duty waivers limit organic company growth and innovation
Women buy from women, men buy from women and men
How employee opinion impacts CEO dismissal
Keeping it in family can be good news when it comes to CEOs
Over a third of office workers are hybrid 'misfits'
 

CRIME

Glencore to pay Republic of Congo $180 mln over alleged corruption claims

Fraudsters target water infrastructure projects, OLAF closes several cases
Rhode Island man to pay more than $2.8 million in restitution for virtual currency fraud
Switzerland fines ABB $4.3 mn over South Africa bribery
New Mexico AG announces $58.5 million opioid settlement with Smith’s Food and drug parent Kroger
Florida AG announces multistate action against CarMax over the disclosure of safety recalls
 

Magazine

TRAVEL

All aboard the Heathrow Festive Express

Asuncion, Mother of Cities and Paraguay’s center of culture, music and shopping
"Pets with Love" Dog Adoption Carnival 2022 to be held in Hong Kong
Weather-resistant ArtWalk Downtown Billings, Montana
Dual branded Courtyard and Residence Inn by Marriott Hotel opens in Montreal
Candlewood Suites Hotel opens in Aberdeen, Md.
 

SEA, LAND, AIR

Lamborghini Huracán Sterrato, first super sports car for any terrain

New colorful Porsche 718 Style Edition models
2023 Toyota Prius Prime, solar panel roof and reliability
Volvo EX90, a car with updates
Cessna Citation CJ4 Gen2 jet, pursue your business goals while enjoying journey
GMC first Sierra EV marks turning point
 

DESIGN

Patchwork carpets, vintage Persian carpets made with unparalleled skill

Real life wallpapers, perfectly executed
A. Lange & Söhne, men's watches with true Saxonian DNA
Nella Vetrina, luxurious Italian designers bathroom vanities and furniture
Karastan rugs, durable and beautiful
Leather bags for every occasion and every life style
 

GADGETS

ASUS launches ExpertBook B9 for executives

Take Elektor Fortissimo and make your own high-end amplifier
RangeXTD, a Wi-Fi extender that actually works
Monitor II A.N.C. headphones, iconic Marshall sound
Zebra TC15, a clever mix of a mobile phone and a computer for business use
Bathroom speakers will make your relaxing even better
 

HEALTH

Cornwall first area in England to trial NHS Digital Health Check

Huge rise of scarlet fever cases in UK, 6 kids dead of Strep A
Neglecting COVID this year created perfect conditions for deadly new variant
EMA recommends withdrawal of pholcodine medicines from EU market
Nearly 200 sick in EU and UK Salmonella outbreak
FDA bans Eli Lilly, Regeneron antibody use in COVID-19 patients infected by omicron
 

MEANTIME

China's two meteorological satellites put into operation

Lagoon dries up as drought grips Peru
Mysteriously bright flash is black hole jet pointing straight toward Earth
Researchers discover Egypt's oldest tomb oriented to winter solstice
China's latest manned space mission blasts off
Astrophysicists hunt for second-closest supermassive black hole